Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Riliprubart, an antibody targeting C1s.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Rademikibart, an antibody targeting IL-4Ralpha.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Nisevokitug, an antibody targeting TGF-beta1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Mevonlerbart, an antibody targeting Fel d 1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Gotistobart, an antibody targeting CTLA-4.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Freneslerbart, an antibody targeting Fel d 1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ersodetug, an antibody targeting Insulin receptor.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Empasiprubart, an antibody targeting C2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Denecimig, an antibody targeting Factor IX × Factor X.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Delpacibart, an antibody targeting CD71.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Dazukibart, an antibody targeting IFNB1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Brenetafusp, an antibody targeting CD3.